Search

Your search keyword '"Wanner C"' showing total 1,726 results

Search Constraints

Start Over You searched for: Author "Wanner C" Remove constraint Author: "Wanner C"
1,726 results on '"Wanner C"'

Search Results

1. Advances in the management of cardiovascular risk for patients with type 2 diabetes: perspectives from the Academy for Cardiovascular Risk, Outcomes and Safety Studies in Type 2 Diabetes

2. Impact of primary kidney disease on the effects of empagliflozin in patients with chronic kidney disease: secondary analyses of the EMPA-KIDNEY trial

3. Effects of empagliflozin on progression of chronic kidney disease: a prespecified secondary analysis from the empa-kidney trial

5. Empagliflozin in the treatment of heart failure with reduced ejection fraction in addition to background therapies and therapeutic combinations (EMPEROR-Reduced): a post-hoc analysis of a randomised, double-blind trial

10. Numerical modeling of cold magmatic CO2 flux measurements for the exploration of hidden geothermal systems

12. Processes controlling δ7Li in rivers illuminated by study of streams and groundwaters draining basalts

13. Pulse pressure and mortality in the 4D study

14. The relationship between uremic toxins and symptoms in older men and women with advanced chronic kidney disease

15. A proposed nomenclature and diagnostic criteria for protein-energy wasting in acute and chronic kidney disease.

17. Impact of outcome adjudication in kidney disease trials: observations from the Study of Heart and Renal Protection (SHARP)

18. From WEDA to EDTA to ERA: 60 years of supporting European nephrology and counting

19. Cost-effectiveness of Simvastatin plus Ezetimibe for Cardiovascular Prevention in CKD: Results of the Study of Heart and Renal Protection (SHARP)

20. Fabry-Krankheit

21. In patients with type 2 diabetes chronic kidney disease is a modifiable cardiovascular risk factor

22. Causes of death in patients with chronic kidney disease: insights from the ASCEND-D and ASCEND-ND cardiovascular outcomes trials

23. Association of heart rate with heart failure outcomes and the effects of empagliflozin in patients with preserved ejection fraction – EMPEROR-Preserved trial

26. The association between TMAO, CMPF, and clinical outcomes in advanced chronic kidney disease: results from the European QUALity (EQUAL) Study

27. Long-term safety and efficacy of anacetrapib in patients with atherosclerotic vascular disease

28. Renal function decline in older men and women with advanced chronic kidney disease-results from the EQUAL study

33. Understanding and modifying Fabry disease: Rationale and design of a pivotal Phase 3 study and results from a patient-reported outcome validation study

36. Reply to 'Depression and clinical outcomes in CKD: do anti-depressants play a role? (EQUAL Study)'

37. Converting from face-to-face to postal follow-up and its effects on participant retention, response rates and errors:lessons from the EQUAL study in the UK

38. Health-related quality-of-life trajectories over time in older men and women with advanced chronic kidney disease

39. Association of longitudinal high-sensitivity troponin T with Mortality in patients with chronic kidney disease

40. ESC 2021 Guideline on the prevention of cardiovascular disease in clinical practice clinical practice

41. 2021 ESC Guidelines on cardiovascular disease prevention in clinical practice

42. 2021 ESC Guidelines on cardiovascular disease prevention in clinical practice

47. Proteinurie

49. Morbus Fabry

50. Evaluation of the effect of sodium–glucose co‐transporter 2 inhibition with empagliflozin on morbidity and mortality of patients with chronic heart failure and a reduced ejection fraction: rationale for and design of the EMPEROR‐Reduced trial

Catalog

Books, media, physical & digital resources